Агренокс и вторичная профилактика ишемических инсультов


Цитировать

Полный текст

Аннотация

Учитывая высокий риск развития повторного инсульта и наличие у больных различных фоновых заболеваний, задача вторичной профилактики инсульта в работе невролога должна стать одной из главных при реабилитации постинсультных пациентов. Профилактика повторного инсульта включает в себя контроль факторов риска. Выделяют модифицируемые и немодифицируемые факторы. К немодифицируемым относятся возраст, пол, этническая принадлежность, наследственная отягощенность и раннее развитие сосудистых заболеваний. В то же время ряд состояний, утяжеляющих течение атеросклероза (артериальная гипертензия, гиперлипидемия, сахарный диабет и курение), может эффективно корректироваться медицинскими вмешательствами. Эти факторы увеличивают риск развития других сосудистых заболеваний. По данным регистра REACH, у 40% из 19 тыс. пациентов с инсультами имеется один или два сосудистых заболеваний других локализаций с вовлечением коронарных и периферических артерий. Ведение пациентов также включает модификацию образа жизни.

Об авторах

Н. В Пизова

Ярославская государственная медицинская академия

Список литературы

  1. Стаховская Л.В., Мешкова К.С., Шеховцова К.В., Скворцова В.И. Дифференцированная вторичная профилактика инсульта: дополнение к рекомендациям. Consilium Medicum. Неврология 2009; 1: 16–8.
  2. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329–39.
  3. Adams R.J., Albers G, Alberts M.J. et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008; 39(5): 1647–52.
  4. Adams R.J. Secondary Prevention of Atherothrombotic Events After Ischemic Stroke. Mayo Clin Proc 2009; 84(1): 43–51.
  5. Albers G.W., Amarenco P, Easton J.D. et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thombolytic Therapy. Chest 2004; 126(3; suppl): 483S–512.
  6. Algra A, van Gijn. Cumulative meta - analysis of aspirin efficacy after cerebral ischaemia of arterial origin. J Neurol Neurosurg Psychiatry 1999; 66: 255.
  7. Anderson J.L., Adams C.D., Antman E.M. et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non – ST - elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008; 117(9): e180.
  8. Antithrombotic Trialists\' Collaboration. Collaborative meta - analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71–86.
  9. Barnett H.J., Eliasziw M, Meldrum H. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995; 332: 238–48.
  10. Bhatt D.L., Steg P.G., Ohman E.M. et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006; 295: 180–9.
  11. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996; 348: 1329–39.
  12. Chimowitz M.I., Lynn M.J., Howlett-Smith H et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305–16.
  13. Coull A.J., Lovett J.K., Rothwell P.M. Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004; 328: 326.
  14. Coutts S.B., Hill M.D., Campos C.R. et al. Recurrent Events in Transient Ischemic Attack and Minor Stroke. What Events Are Happening and to Which Patients? Stroke 2008; 39: 2461–6.
  15. Dennis M.S., Bamford J.M., Sandercock P.A.G., Warlow C.P. A comparison of risk factors and prognosis for transient ischemic attacks and minor ischemic strokes. Stroke 1989; 20: 1494–9.
  16. Diener H.C., Cunha L, Forbes C et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143: 1–13.
  17. Diener H.C., Bogousslavsky J, Brass L.M. et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high - risk patients (MATCH): randomised, double - blind, placebo - controlled trial. Lancet 2004; 364: 331–7.
  18. Diener H.C., Sacco R, Yusuf S. Rationale, design and baseline data of a randomized, double - blind, controlled trial comparing two antithrombotic regimens (a fixed - dose combination of extended - release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007; 23: 368–80.
  19. Diener H.C., Sacco R.L., Yusuf S et al. Effects of aspirin plus extended - release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double - blind, active and placebo - controlled study. Lancet. Neurology 2008; 8: 1–10.
  20. Dhamoon M.S., Sciacca R.R., Rundek T et al. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology 2006; 66: 641–6.
  21. Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325(18): 1261–6.
  22. Eliasziw M, Kennedy J, Hill M.D. et al. North Am Symptomatic Carotid Endarterectomy Trial Group. Early risk of stroke after a transient ischemic attack in patients with internal carotid artery disease. CMAJ 2004; 170: 1105–9.
  23. European Stroke Organization (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25: 457–507.
  24. Friedman G.D., Wilson W.S., Mosier J.M. et al. Transient ischemic attacks in a community. JAMA 1969; 210: 1428–34.
  25. Gent M, Blakely J.A., Easton J.D. et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1: 1215–20.
  26. Goldstein L.B., Adams R, Alberts M.J. et al. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2006; 114(22): e617.
  27. Hass W.K., Easton J.D., Adams H.P. et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501–7.
  28. Hill M.D., Yiannakoulias N, Jeerakathil T et al. The high risk of stroke immediately after transient ischemic attack: a population - based study. Neurology 2004; 62: 2015–20.
  29. Johnson E.S., Lanes S.F., Wentworth C.E. III et al. A metaregression analysis of the dose - response effect of aspirin on stroke. Arch Intern Med 1999; 159: 1248–53.
  30. Johnston S.C., Gress D.R., Browner W.S., Sidney S. Short - term prognosis after emergency department diagnosis of TIA. JAMA 2000; 284: 2901–6.
  31. Mohr J.P., Thompson J.L.P., Lazar R.M. et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444–51.
  32. Sacco R.L., Adams R, Albers G et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Co - sponsored by the Council on Cardiovascular Radiology and Intervention. The American Academy of Neurology affirms the value of this guideline. Stroke 2006; 37: 577–617.
  33. Sacco R.L., Diener H.C., Yusuf S et al. PRoFESS Study Group. Aspirin and extended - release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med. 2008; 359(12): 1238–51.
  34. SALT Collaborative Group. Swedish Aspirin Low - Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 1991; 338(8779): 1345–9.
  35. Sze P.C., Reitman D, Pincus M.M. et al. Antiplatelet agents in the secondary prevention of stroke: meta - analysis of the randomized control trials. Stroke 1988; 19(4): 436–42.
  36. Talelli P, Greenwood R.J. Review: Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes? Therapeutic Advances in Cardiovascular Disease 2008; 2(5): 387–405.
  37. The ESPRIT Study Group. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367: 1665–73.
  38. The ESPRIT Study Group. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet. Neurol 2007; 6: 115–24.
  39. Thom T, Haase N, Rosamond W et al. Heart disease and stroke statistics to 2006 update. A report from the American Heart Association Statistics Committee and the Stroke Statistics Subcommittee. Circulation 2006; 113: e85–151.
  40. Verro P, Gorelick P.B., Nguyen D. Aspirin Plus Dipyridamole Versus Aspirin for Prevention of Vascular Events After Stroke or TIA. A Meta - Analysis. Stroke 2008; 39: 1358–63.
  41. Whisnant J.P., Matsumoto N, Elveback L.R. Transient cerebral ischemic attacks in a community. Mayo Clin Proc 1973; 48: 194–8.

© ООО "Консилиум Медикум", 2009

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах